Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma - PubMed (original) (raw)

Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma

D M Eccles et al. Br J Cancer. 1992 Jan.

Free PMC article

Abstract

Mouse monoclonal antibodies PAb 240 and PAb 1801 which specifically immunoprecipitate p53 protein, were used to examine 27 fresh ovarian tumours (16 serous adenocarcinomas, six endometrioid carcinomas, one mucinous adenocarcinoma, one mucinous borderline tumour and three benign adenomas). Eleven out of 16 (69%) serous adenocarcinomas and one endometrioid tumour showed positive staining with one or both antibodies and none of the mucinous or benign tumours stained with either antibody. DNA from tumour and peripheral blood leukocytes was used to identify allelic deletions on chromosome 17p in tumours. 11/12 positively staining tumours showed less of heterozygosity (LOH) on 17p at the nearest informative locus to the p53 gene. In this series of ovarian tumours, LOH on 17p correlates closely with the aberrant expression of the p53 protein in a high proportion of advanced stage serous adenocarcinomas. This observation suggests that the p53 tumour suppressor gene is involved in the evolution of epithelial ovarian cancer (EOC) and may have prognostic significance.

PubMed Disclaimer

Cited by

p53 mutations in cervical carcinogenesis--low frequency and lack of correlation with human papillomavirus status.
Busby-Earle RM, Steel CM, Williams AR, Cohen B, Bird CC. Busby-Earle RM, et al. Br J Cancer. 1994 Apr;69(4):732-7. doi: 10.1038/bjc.1994.138. Br J Cancer. 1994. PMID: 8142262 Free PMC article.
Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlation with sex steroid receptor status.
Koshiyama M, Konishi I, Wang DP, Mandai M, Komatsu T, Yamamoto S, Nanbu K, Naito MF, Mori T. Koshiyama M, et al. Virchows Arch A Pathol Anat Histopathol. 1993;423(4):265-71. doi: 10.1007/BF01606889. Virchows Arch A Pathol Anat Histopathol. 1993. PMID: 8236823
p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study.
Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, Cosio S, Gagetti O, Genazzani AR, Bevilacqua G. Buttitta F, et al. Br J Cancer. 1997;75(2):230-5. doi: 10.1038/bjc.1997.38. Br J Cancer. 1997. PMID: 9010031 Free PMC article.
p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer.
Ferrandina G, Fagotti A, Salerno MG, Natali PG, Mottolese M, Maneschi F, De Pasqua A, Benedetti-Panici P, Mancuso S, Scambia G. Ferrandina G, et al. Br J Cancer. 1999 Oct;81(4):733-40. doi: 10.1038/sj.bjc.6690756. Br J Cancer. 1999. PMID: 10574264 Free PMC article.
Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid.
van den Berg FM, Baas IO, Polak MM, Offerhaus GJ. van den Berg FM, et al. Am J Pathol. 1993 Feb;142(2):381-5. Am J Pathol. 1993. PMID: 8434637 Free PMC article.

References

1. Nature. 1986 Mar 6-12;320(6057):84-5 - PubMed
1. Nature. 1979 Mar 15;278(5701):261-3 - PubMed
1. EMBO J. 1990 May;9(5):1595-602 - PubMed
1. Oncogene. 1990 Jun;5(6):893-9 - PubMed
1. Lancet. 1990 Mar 24;335(8691):675-9 - PubMed

Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma - PubMed (original) (raw)